Research identifies new targets for multiple myeloma treatment
New research published in the Clinical Lymphoma, Myeloma & Leukemia journal has confirmed that Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are promising therapeutic targets for the treatment of multiple myeloma.
These antigens are present on malignant plasma cells but absent on normal plasma cells, meaning that any therapeutics which target them could prove capable of precisely treating multiple myeloma as well as a broad spectrum of other plasma-cell disorders.
Current therapies targeting BCMA, CD38 and SLAM7 dominate the multiple myeloma market, but these targets are found on both healthy and malignant cells.
The study was sponsored by HaemaLogiX in partnership with Sydney University/The University of Melbourne.
It demonstrated that KMA and LMA are consistently expressed across the disease spectrum – from early pre-malignant stages such as monoclonal gammopathy of undetermined significance (MGUS) through to treated myeloma – and they increase as the disease progresses. This makes them highly specific, reliable markers for detecting myeloma plasma cells and particularly attractive targets for next-generation antibody and cell-based immunotherapies.
Dr Rosanne Dunn, Co-Founder, Executive Director and CSO at HaemaLogiX, said: “This study confirms that patients with kappa-type myeloma (70%) are likely to express KMA and those with lambda-type (30%) disease are likely to express LMA, establishing relevant targets for our immunotherapies that are currently in clinical and preclinical development.
“We are advancing KappaMab, which targets KMA, in a Phase IIb clinical trial in patients whose disease is relapsing after treatment with three classes of drug. Previous clinical studies with KappaMab have shown that the antibody does not cause damage to normal immune cells and it was highly effective in combination with Revlimid and dexamethasone, which are commonly used in the treatment of myeloma. The KMA targeted CAR-T cell is currently progressing to a Phase I clinical trial in relapsed/refractory myeloma patients.”
